relatlimab,nivolumab
bms
['melanoma', 'nivo']
nivo/rela for #uveal #melanoma, 10% response rate. still not the breakthrough we were looking for. #smr2022 
Medical oncologist, @lemelbaum institute for immuno-oncology. Treating patients with #Melanoma, interested in #Immunotherapy and clinical trials